







an Open Access Journal by MDPI

Bacteria-Based Therapy to Fight Cancer

Guest Editor:

Prof. Esther Julián

Department of Genetics and Microbiology, C Building, Autonomous University of Barcelona, 08193 Bellaterra (Barcelona), Spain.

Deadline for manuscript submissions:

closed (1 February 2022)

Message from the Guest Editor

Mycobacterium bovis BCG is still the preferred treatment option for high-risk non-muscle-invasive bladder cancer. Currently, the search for safe bacteria with antitumor properties is one of the subjects at the forefront of cancer research. This includes species of Mycobacterium, Salmonella, Escherichia, Clostridium, Bifidobacterium or Lactobacillus genera, among others. Bacteria can help to fight cancer in different ways. Some species can reach tumour sites and directly inhibit tumour growth by themselves, or can be carriers to express or deliver antitumor molecules. In addition, bacteria innately interact with the immune system. This ensures that bacteria are ideal tools to modulate the tumour microenvironment. leading to an anticancer response. Moreover, bacteria can be also combined with other cancer treatments such chemotherapy, radiotherapy, targeted agents or other immunotherapies as checkpoint inhibitors to enhance or complement their efficacy and/or reduce their adverse events. This Special issue will focus on the use of cancerfighting bacteria as monotherapy or in combination with other therapeutic options.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us